Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Field Trip Health (FTRP) has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange
  • The listing is subject to the company fulfilling the terms of its conditional approval letter
  • Once the company receives approval, Field Trip’s common shares will be delisted from the CSE and commence trading on the TSX under the symbol FTRP
  • Field Trip is a global leader in the development and delivery of psychedelic therapies
  • Field Trip Health Ltd. (FTRP) opened trading at C$5.64 per share

Field Trip Health (FTRP) has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX).

The listing is subject to the company fulfilling the terms of its conditional approval letter dated May 26, 2021.

Field Trip is actively working to satisfy the requirements and conditions that were highlighted in the approval letter and management is confident that all conditions for listing will be met in the coming weeks.

Upon obtaining final approval, the Company will issue an additional press release to inform shareholders when it anticipates that its common shares will commence trading on the TSX.

Upon completion of the final listing requirements, the company’s common shares will be delisted from the CSE and commence trading on the TSX under the trading symbol FTRP. Warrants will trade under the symbol FTRP-WT.

The company’s shares will continue to trade on the OTCQX market under the symbol FTRPF.

Joseph del Moral, Chief Executive Officer of Field Trip, said,

“Receiving conditional acceptance to move to Canada’s largest exchange is a significant milestone for Field Trip and the emerging psychedelics industry more broadly. While our listing on the TSX will provide greater visibility for Field Trip in the markets and broaden our access to additional Canadian and international investors, we continue to work towards further enhancing liquidity for global investors in Field Trip, including exploring cross-listings onto US exchanges.”

Field Trip is a global leader in the development and delivery of psychedelic therapies.

Field Trip Health Ltd. (FTRP) opened trading at C$5.64 per share.

More From The Market Herald

" Optimi Health (CSE:OPTI) signs psilocybin supply agreement with Halucenex Life Sciences

Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.